ESC 365 - Scenario 3 - Long-term safety of new anti-diabetic drugs.

ESC Premium Access

Scenario 3 - Long-term safety of new anti-diabetic drugs.

Session: Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor A. Niessner (Vienna, AT)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Alexander Niessner

Medical University of Vienna, Vienna (Austria)

9 presentations

2 followers

5 more presentations in this session

Safety first: avoiding adverse events with new cardiovascular drugs - Panel

Introduction - Safety first: avoiding adverse events with new cardiovascular drugs

Speaker: Doctor M. Alonso Garcia (London, GB)

Scenario 1 - Adverse events of new lipid lowering drugs.

Speaker: Doctor T. Hall (Oslo, NO)

Scenario 2 - Neprilysin inhibitors in heart failure: safety and adverse events

Speaker: Assistant Professor M. Kaluzna-Oleksy (Poznan, PL)

Safety first: avoiding adverse events with new cardiovascular drugs - Take Home Message.

Speaker: Professor J. Tamargo (Madrid, ES)

Access the full session

Meet the Experts - Safety first: avoiding adverse events with new cardiovascular drugs

Speakers: Professor A. Niessner, Doctor M. Alonso Garcia, Doctor T. Hall, Assistant Professor M. Kaluzna-Oleksy, Professor J. Tamargo

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources